ERBB2 and breast carcinoma: Previous epigenetic analyses have identified aberrant DNA methylation signatures associated with molecular subtypes of breast cancer through hormone-receptor and human epidermal growth factor 2 (HER2) status [21-23]; however, very limited information is available on global methylation changes associated with each molecular subtype, as previous studies focused on individual candidate tumor-suppressor genes by using locus-specific methods.